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ABSTRACT
BACKGROUND
Surgery is usually the primary treatment of Head and neck cancer (HNC). It causes 
significant morbidity and large surgical defects that usually require microvascular 
reconstruction to restore the tissue deficiency. Treatments of these very challenging 
areas are associated with psychological disruption of life. Unfortunately, the 
studies of long-term Health-related quality of life (HRQoL) after microvascular 
reconstruction surgery of HNC are scarce. Complications related to microvascular 
surgery are quite rare, but they can be devastating. Prolonged treatment periods 
often exacerbate complications and therefore delay adjuvant oncologic treatments. 
Glucocorticoids (GCs) are widely used perioperatively to diminish immediate 
postoperative complications such as PONV, pain and swelling, but the evidence 
of their safety is unclear. Complex surgery of HNC and postoperative complications 
may influence survival and patients high long-term mortality is common. 
AIM
This thesis is focused on three main aims: first, to evaluate whether the perioperative 
use of dexamethasone in reconstructive HNC surgery is beneficial (Study I-II); 
second, to evaluate the long-term HRQoL compared with an age- and gender-
standardized sample of the general population (Study III); and third, to investigate 
whether the use of perioperative dexamethasone affects short-term mortality in 
HNC patients and to analyze the predictors affecting long-term mortality (Study IV). 
PATIENTS AND METHODS
This study consisted of a prospective, double-blind randomized group of 93 HNC 
patients with a microvascular reconstruction operated at the Department of Oral 
and Maxillofacial Surgery and Department of Plastic Surgery in Helsinki University 
Hospital in Finland between December 2008 and February 2013. Patients were 
randomized into two groups, 51 patients received dexamethasone (DEX) and 42 
served as a control group (NON-DEX). Patients in the study group received 10 
mg dexamethasone intravenously (IV) every 8 h on the first day, every 12 h on the 
second day and once on the third day, total amount of dexamethasone being 60 
11
mg. In studies I, II, and IV, the data was analyzed depending on randomization, 
in Study III, the data was analyzed for all patients independent of randomization. 
RESULTS
Patients who received dexamethasone had significantly more major complications, 
especially surgical infections (p=0.012), and need for second surgery within three 
weeks. Dexamethasone use failed to diminish the amount of neck swelling, length 
of stay in the intensive care unit (ICU) or hospital, or duration of intubation or 
tracheostomy (Study I).
The use of dexamethasone did not reduce postoperative nausea and vomiting 
(PONV) in five days (p>0.05). Patients in the DEX-group received less oxycodone in 
five days postoperatively (p=0.040) and reported significantly less pain (p=0.030). 
Patients required significantly more insulin and lactate levels were higher (p<0.001)
(Study II).
The long-term (4.9-years) HRQoL of operated HNC patients was significantly 
lower than at baseline (p=0.010). The most affected dimensions were “speech” 
and “usual activities” at the end of follow-up. The HRQoL was a significantly lower 
in HNC patients as compared with the general population (p=0.014)(Study III).
Perioperative use of dexamethasone was associated with higher short-term 
mortality in reconstructive HNC surgery. During the first year, more deaths 
occurred in the DEX group than in the NON-DEX group: at one month 4% vs 0%, 
at six months 14% vs 0% and at 12 months 22% vs 5% (p=0.043). HNC was the 
primary cause of death in most of the deceased (79%). The most important long-
term predictors of death were distant metastases (p<0.001), CCI 5-9 (p<0.001), 
and the use of perioperative dexamethasone (p=0.004)(Study IV).
CONCLUSIONS
The results of this thesis conclude that the perioperative use of dexamethasone 
is not recommended for reconstructive HNC patients requiring microvascular 
reconstruction. It is associated with major complications and higher short-term 
morbidity, and it does not seem to significantly enhance immediate post-operative 
recovery or shorten ICU or hospital stay. Long-term HRQoL was significantly 
reduced and speech and usual activities were the most affected dimensions up 
to 4.9-years after the operation in the whole patient cohort. There is more harm 
than benefit of the perioperative use of dexamethasone with reconstructive HNC 
patients.
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1. INTRODUCTION
Head and neck cancer (HNC) is the sixth most common malignancy in the 
world and its incidence is increasing worldwide. In Finland, over 800 patients 
are diagnosed annually, constituting 2.5% of all new malignant diagnoses (1, 2). 
HNC includes malignant neoplasms of the oral cavity, oropharynx, nasopharynx, 
hypopharynx, larynx, salivary glands, upper esophagus, paranasal sinuses, nasal 
cavity, and skin. The treatment options vary from surgery to oncological treatments, 
or combinations of these. The primary treatment of HNC is often surgical resection 
of the tumor and affected lymph nodes in the neck area. Anatomically demanding 
surgery often causes large surgical defects that require free flaps to restore the tissue 
deficiency. In comparison to regional flaps, microvascular reconstruction is a more 
complicated surgery, but extremely reliable in achieving successful reconstruction 
in HNC (3).
Treatments of HNC, including surgery and possible oncological treatments, 
are associated with enormous psychological disruption of life by causing physical, 
aesthetic, and functional disability. HRQoL has become an important outcome 
in HNC treatment and there are many different disease-specific and generic 
HRQoL questionnaires to measure it (4, 5). The studies of long-term HRQoL 
after microvascular reconstruction surgery of HNC are scarce.
HNC surgery can cause many postoperative disadvantages, like respiratory 
problems caused by neck swelling, prolonged ICU and hospital stay, pain and 
PONV. GCs are widely used perioperatively to improve patient’s recovery problems 
although the safety of their use with this patient group has not been studied earlier 
with prospective, randomized studies (6-8). 
Complex surgery of HNC and postoperative complications may influence 
survival and high long-term mortality is common. Even if the disease-specific 
survival (DSS) has improved from 55% to 66% over the last decades, five-year 
overall survival (OS) has been reported to be around 50–60% (9-12). According to 
the literature, the presence of lymph node metastasis, invasion, tumor recurrence, 
postoperative complications, and advanced age have been described to be associated 
with worsened survival, but the results are controversial (10, 13, 14). The number 
of studies focusing on mortality after reconstructive surgery of HNC is limited. 
Early postoperative deaths are rare, but they occur in all major surgeries, thus it is 
important to analyze the mortality and associated factors also with reconstructive 
HNC patients.
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2. REVIEW OF THE LITERATURE
2.1 HEAD AND NECK CANCER
Head and neck cancer is the sixth most common cancer worldwide and it includes 
cancers of the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, salivary 
glands, upper esophagus, paranasal sinuses, nasal cavity, and skin (15, 16). HNC 
comprises 2.5% of all new malignant diagnoses in Finland: with a population of 5.5 
million people, over 800 new cases are reported annually, the majority occurring 
in men (1, 2, 17). The most common cancer is squamous cell carcinoma (SCC), 
which accounts for 90% of the head and neck malignancies. Other malignant 
neoplasms include sarcomas, lymphoma, malignant melanomas, metastases of 
other malignancies, and various carcinomas of the salivary glands.
2.1.1 ETIOLOGY, INCIDENCE, AND SURVIVAL
Smoking and alcohol consumption are both main independent risk factors that 
have been associated with the incidence of HNC. The interaction between tobacco 
and alcohol has been explored in several studies. In a pooled analysis of 18 case-
control studies, Hashibe et al. reported that in users of tobacco and alcohol in 
Latin America, the overall risk of HNC was 10 times higher compared with never-
users (18). The risk of developing HNC increases with the intensity and duration 
of smoking (19). Garrote et al. reported effective findings in their case-control 
study of 200 patients in Cuba where heavy alcohol users (> 21 drinks per week) 
and heavy smokers (>30 cigarettes per day) had a 111-fold risk of HNC than non-
consumers. In the same study former drinkers who continued heavy smoking had 
still a 33.6-fold risk (20).
More recently the role of human papillomavirus (HPV) infection has been 
increasingly recognized and HPV-related tumors (HPV-16) represent a different 
biological, epidemiological and clinical subset of HNC that are represented more 
frequently with younger patients (aged < 60 years). The study of Mehanna et al. 
showed that 55% of 654 oropharyngeal SCC cases were HPV-16 positive (21). 
HPV-positive HNC:s (particularly oropharyngeal tumors) appear to have a more 
favorable OS rate compared with HPV-negative diseases (22). 
The incidence of HNC is increasing in Finland (1, 17). Complex surgery for 
HNC may influence survival and high long-term mortality is common as five-year 
survival has been reported to be around 50% (10, 23-25). Typically, a patient’s 
prognosis is based on tumor, node, and metastasis (TNM) classification. Staging 
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is an important tool for surgeons and oncologists to define a proper treatment and 
predict prognosis for each cancer. Periodic updates to staging systems are necessary 
and the latest update became effective in 2018, when oral cavity cancers began to 
also be staged by the depth of invasion. This novel staging system was introduced 
for HPV-associated oropharyngeal cancers and extra nodal extension began being 
used on all sites, except for nasopharyngeal and high-risk HPV oropharyngeal 
cancers (26, 27). HNC usually sends metastasis to lymph nodes and the most 
prognostic factor is the lymph node status. About 40% of oral cavity and pharynx 
SCC present with regional metastasis (28).
2.1.2 TREATMENT OF HNC
The treatment of HNC depends on a number of factors, including the location and 
the stage of the cancer and patient’s general health. Treatment for HNC usually 
includes surgery, radiation therapy, chemotherapy, or a combination of treatments.
Surgery remains the primary treatment modality, especially for oral cancer. 
The primary surgical resection of the tumor with free margins and the dissection 
of the locoregional lymph nodes (neck dissection) is the most important goal of 
surgery without delaying possible adjuvant oncological treatment. Surgical margins 
are considered to be free when the specimen includes a five mm wide resection 
evaluated by a pathologist, and close when including a zero to five mm resection. 
Positive and close margins have negative impact on survival and recurrence (29, 
30). The degree of the tumor and possible metastasis are evaluated preoperatively 
using Multislice computerized tomography (MSCT), Magnetic resonance imaging 
(MRI), ultrasound (US), or Positron emission tomography (PET) imaging. The 
treatment for early-stage SCC tumors (T1–T2) is usually single modality with 
surgery, while locally advanced larger (T3–T4) tumors are treated with surgery 
followed by adjuvant oncological treatment or with only definite oncological 
treatment (chemoradiation) (31, 32). In Finland, the most common radiation 
technique is intensity-modulated radiotherapy (IMRT), which can be combined 
with chemotherapy—usually Cisplatin. Adjuvant radiation dose after primary 
surgery is approximately 60–66 Gy to the primary site and node positive neck. 
Treatment of oropharyngeal SCC (OPSCC) has changed toward a more 
oncologic approach during the last decades. The main reason for this is human 
papillomavirus (HPV) (33). Radiotherapy and oncological modalities are used as 
a primary treatment, especially on the tonsils or base of tongue area with human 
papillomavirus 16 positive (HPV16) patients and for inoperable patients (34). 
The HPV-associated form of OPSCC has been considered to have different cancer 
biology and has been shown to have better treatment response and survival than 
HPV-negative OPSCC (35). Relatively new oncological treatment methods include 
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modern immunotherapy with immunomodulating antibodies, which is designed 
to boost the body’s natural defenses to fight the cancer with recurrent and/or 
metastatic HNC (36). 
2.1.3 MICROVASCULAR RECONSTRUCTIONS OF HNC
The surgical closure of the defect includes direct closure of the wound, healing 
by secondary intention, skin or mucosal grafting, local flaps, pedicled flaps, and 
more complex free microvascular tissue transfer. In this study all patient cases 
included only surgery with microvascular reconstructions. Curative treatment of 
the HNC usually includes ablative surgery and microvascular reconstruction should 
be considered whenever reconstruction for surgical defects is needed and cancer 
is still operable (37–39). In extensive ablative cases, when the resection of facial 
nerve causes severe functional and esthetic disadvantages, the primary facial nerve 
reconstruction should also be considered to improve patients Quality of life (QoL) 
(40). Free flap surgery (FFS) have been in routine use in HNC for 20–30 years 
and was first introduced in HNC more than 50 years ago (41, 42). FFS is used as a 
standard reconstruction method when local or regional flaps are inadequate, when 
the result would cause significant loss of normal form and function, or when it could 
lead to a deterioration in the HRQoL (9, 43–45). FFS is technically demanding, each 
case is unique, and indications and contraindications should be carefully evaluated 
for each patient to achieve optimal results and minimize complications. Even if 
free flaps are extremely reliable in achieving successful reconstruction in skilled 
hands, complications and flap losses do occur which usually leads to a secondary 
FFS and can be devastating (46). Patients age is not a contraindication for FFS, 
as methods have been safe among the elderly as well (47).
2.1.4 FLAPS
There are numerous possibilities for free flap donor sites in HNC and the selection 
of the flap depends on the localization of the cancer, type of needed tissue, 
anatomical considerations, patient characteristics, and surgeons experience. More 
than 20 donor sites for FFS in HNC have been introduced during the last 30 
years (42, 48). Free flaps can contain different tissue needed for reconstruction 
(skin, subcutis, muscle, bone) and they are usually classified according to their 
constituents as fasciocutaneous flaps (skin, fat, and fascia), muscle flaps (muscle), 
osseous flaps (bone), and combinations of these (osteocutaneous, myocutaneous, 
osteomusculocutaneous).
16
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2.1.4.1 Soft tissue flaps
Radial forearm flap (RFA) has been widely used in HNC since the 1980s as described 
by Muhlbauer in 1982 (49, 50). The skin flap is harvested with superficial fat, the 
radial artery, concomitant veins and cephalic vein. It is extremely reliable, and 
anastomoses are usually easy to perform because vessels are large in diameter 
and the pedicle is long. Its advantages are a long vascular pedicle, and its thin, 
versatile soft tissue. The limitations of the flap include its relatively small size and 
visible donor-site. 
Anterolateral thigh flap (ALT) as first published by Song et al. 1984 (51) 
and popularized by Koshima et al. in 1989 (52) is based on septocutaneous 
and musculocutaneous perforators of the descending branch of the lateral 
circumflex femoral artery and can be lifted as a subcutaneous, fasciocutaneous, 
or myocutaneous flap. It is reliable, harvesting is straight-forward, and there is a 
minimal donor-site morbidity (53). 
Latissimus dorsi (LD) free flap as first described in HNC reconstruction in 
1978 by Quillen et al. (54) is widely used in HNC surgery. It has a long pedicle 
(thoracodorsal vessels), which is unlikely to become affected by atherosclerosis 
and it offers a good stock of soft tissue. Other options for soft tissue flaps used in 
HNC surgery include several variations of the rectus muscle (55), ulnar artery flap 
(56), the median sural artery perforator flap (57), and temporal artery posterior 
auricular skin (TAPAS) flap (58).
2.1.4.2 Composite flaps
In complex HNC surgery with bony defect, vascularized bone grafts offer a better 
tool to achieve both structural stability and soft tissue support for anatomical 
and functional end results compared with soft-tissue flaps. The osseocutaneous 
fibular free flap is probably the most popular option used in composite HNC 
reconstruction because of its many advantages. It was first introduced for 
mandibular reconstruction in 1991 by Germain et al. (59). It has low donor-site 
morbidity, harvesting with two team approach simultaneously is relatively easy and 
the flap provides a good length of vascularized bone. Limited size of soft-tissue is 
its primary disadvantage. The deep circumflex iliac artery (DCIA) flap presented in 
1979 by Taylor et al. (60) is widely used in HNC surgery and offers a thick, bulky 
bone with natural anatomic curvature for especially angular and corpus defects. The 
disadvantages include donor-site morbidity, a slightly more challenging elevation, 
and a limited length of pedicle. The scapular bone flap (61) is a very versatile flap 
with alternative soft tissue components and is widely used in HNC. The flap is 
well-suited for large defects and the donor-site morbidity is low. The drawbacks 
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include relatively thin bone material for dental rehabilitation (62) and harvesting 
requires repositioning of the patient. Wilkman et al. compared the three most 
used composite flaps (a total of 163 patients, scapular, fibular, and iliac crest) in 
maxillofacial reconstructions in Helsinki University Hospital and found that the 
deep circumflex iliac artery flap was the least reliable alternative of these (63).
In Finland, microvascular reconstructions have been the first choice for 
reconstruction since the 1990s. New flap variations are being developed with the 
aim to customize the choice of flap individually for every patient to achieve the 
best possible result. In recent years, the range of flaps has expanded. A chimeric 
flap provides diverse tissue types from a single donor site. It is composed of more 
than one flap that each have an independent vascular supply but in turn are joined 
to a single pedicle and its advantage includes the independent mobility of skin, 
muscle, and bone (64). Many combinations can be created, and the proportion 
of chimeric flaps have increased (65, 66). Examples of chimeric flaps include, 
for example, serratus-latissimus-scapular component flap and anterolateral thigh 
chimeric flap types. Husso et al. retrospectively analyzed the trends of microvascular 
reconstructions in the head and neck area between 1995–2012 at the Department of 
Plastic Surgery, Helsinki University Hospital, Finland and found that the majority 
of free flaps were single fasciocutaneous flaps (Radial forearm (RFA) and ALT) but 
the flap types increased over time, with a total of 24 different flaps (48). 
2.1.5 RISKS AND COMPLICATIONS IN FFS
Many factors may have influenced FFS outcomes. Complications are common 
after microvascular reconstruction of the HNC. Reported rates of the frequency 
ranges between 34–85% (69). Different variables are considered as risk factors 
for complications within this group of patients, including comorbidities, smoking, 
alcohol use, increased age, ASA (American Society of Anesthesiologists) class, long 
duration of anesthesia, tracheostomy, higher tumor stage, and site (3, 67, 68, 
70, 71). There are several tools to classify comorbidities in surgery, including the 
Charlson Comorbidity Index (CCI) score, introduced by Charlson et al. as an index 
of general comorbidity predicting mortality (72).
Vascular complications may jeopardize the survival of the flap and different 
types of free flaps have been shown to have differences in their blood flow. Mucke 
et al. studied changes in perfusion of four different flaps in a prospective study 
of 196 patients and found that after the first postoperative day, the perfusion 
of septocutaneous flaps (RFA) was much better compared with muscular flaps 
(73). Free flaps tolerate ischemia from 4 to 12 hours, thus revision should be 
performed during this time frame to save the flap (74). Most vascular occlusions 
(80%) occur within one to four postoperative days (75). Although, the survival rate 
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of the free flap is generally considered good, 95–98% (76, 77), every flap failure is 
devastating to the patient. The failure of the flap may occur for multiple reasons, 
like harvest of the flap, pedicle compatibility, prolonged ischemia, and inadequate 
postoperative care (78). In a study of 451 HNC FFS patients by Mucke et al., the 
overall free flap failure rate was 4% and revealed significant risks of flap failure 
depending on prior attempts at microvascular transplants (p<0.001 and length 
of hospitalization (p=0.007) (79).
Complications can be detected if the flap is visible and the follow-up meticulous. 
Most surgeons use clinical monitoring techniques, as observation of the flap color 
and turgor and pinprick testing (80, 81). In the hypopharynx or oropharynx area, 
flap can be situated deep and be invisible. The follow-up of these flaps through 
visualization is extremely difficult or even impossible. Doppler ultrasound may also 
be unreliable to use close to carotid arteries. The Licox® tissue oxygen pressure 
monitoring system has also been used to follow postoperative circulation in free 
microvascular flaps (82). There are several monitoring devices to follow the vitality 
of the flap, however many of the methods are quite expensive and no particular 
technique is superior to others (83). 
Different classifications for complications are used but there is no specific 
method for HNC. Complications can be categorized as surgical, such as donor site 
or recipient site, related to surgical ablation or microvascular reconstruction, and 
medical complications including patients’ medical condition. Minor complications 
can be treated with medications or at the bedside, but major wound- or flap-related 
complications may cause serious harm to patients’ overall recovery. In this study, 
surgical complications were classified according to the Clavien-Dindo classification 
published in 1992, which is the most-cited system used in the literature and has 
become more common also in HNC (84, 85). McMahon et al. studied postoperative 
complications after HNC free flap surgery using the Clavien-Dindo classification 
in a prospective of 192 patients and found that a total of 64% had complications, 
and around one third of them were serious (69). The Clavien-Dindo classification 
is presented in Table 1. 
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Table 1. Clavien-Dindo classification 
Grades Definition
Grade I Any deviation from the normal postoperative course without the need for 
pharmacological treatment or surgical interventions. Allowed therapeutic 
drugs as antiemetics, diuretics, antipyretics, and electrolytes, and 
physiotherapy. Allows wound infections opened at the bedside.
Grade II Requiring pharmacological treatment with drugs other than those allowed 
for Grade I complications. Blood transfusions and total parenteral nutrition 
are also included
Grade IIIa Requiring surgical, endoscopic, or radiological intervention
Intervention not under general anesthesia
Grade IIIb Requiring surgical, endoscopic, or radiological intervention 
Intervention under general anesthesia
Grade IV Life-threatening complication requiring IC/ICU-management
IVa Single organ dysfunction (including dialysis)
IVb Multiorgan dysfunction
Grade V Death of a patient
Patients undergoing major HNC operations often need tracheostomy to secure 
the airway during the immediate postoperative period (86). There are no 
evidence-based recommendations for the use of tracheostomy or the timing of 
decannulation because of the variability of these patients and procedures. The 
majority of the patients are admitted to the ICU postoperatively due to careful 
free flap monitoring and controlled weaning off the ventilator, though there is 
no evidence for the positive impact of routine postoperative care in the ICU (87, 
88). Free flap monitoring after surgery should be performed at least hourly for 
the first 24 hours postoperatively (89) to detect possible vascular problems over 
time. Patients earlier irradiation or previously failed microvascular operation 
have been reported to predispose to possible flap failure (78). In a study of 408 
patients of Brown et al, vascular occlusions later than two days after the primary 
operation led to flap loss more often than in days one and two (90). Long hospital 
periods and major postoperative problems are common related side effects due to 
major surgery. Prolonged hospitalization can cause postoperative problems like 
nosocomial infections, as well as increased health care costs and delays to possible 
adjuvant oncological treatments (91).
2.2. GLUCOCORTICOIDS
GCs are a group of steroid hormones, the name is composed from its role in 
regulation of glucose metabolism, synthesis of adrenal cortex and its steroidal 
structure. CCs are part of the feedback mechanism in the immune system. 
The natural GC cortisol is produced and released from the adrenal cortex and 
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controlled by the hypothalamic-pituitary-gland. GCs are involved in a wide variety 
of cardiovascular, metabolic, homeostatic and immunological actions. Synthetic 
GCs act like normal cortisol but have different potencies and biological half-lives. 
2.2.1 SYNTHETIC GLUCOCORTICOIDS IN MEDICINE
Usually GCs are used in medicine to treat diseases caused by overactive immune 
system like allergies, asthma, inflammatory and autoimmune diseases, organ 
transplant rejection, and malignancies of the lymphoid system (92). Their 
immunosuppressive action is well known although their precise mechanism 
remains unclear (93, 94). Various synthetic GCs are available for several 
indications. Synthetic GCs are different regarding their pharmacodynamics and 
can consequently be chosen based on the desired effects (95) (Table 2). For short-
term use (less than one week) GC dosages are usually higher than those used over 
the long-term, and the benefits and side-effects are also different. 
Table 2. Pharmacology of glucocorticoids
Equivalent 
dose  
(mg)
Relative 
mineralocorticoid 
activity
Duration 
of eect 
(h)
Anti-
inflammatory 
potency
Half-time 
in plasma 
(min)
Short-acting
Cortisone 25 1 8–12 1 60
Hydrocortisone 20 0.8 8–12 0.8 90
Intermediate-acting
Prednisone 5 0.25 24–36 4 60
Prednisolone 5 0.25 24–36 4 200
Methylprednisolone 4 0 24–36 5 180
Triamcinolone 4 0 24–36 5 300
Long-acting
Dexamethasone 0.75 0 36–54 25 200
Betamethasone 0.6 0 36–54 25 200
* short: 8–12 hours, intermediate: 12–36 hours, long: 36–54 hours
2.2.2 GLUCOCORTICOIDS IN HEAD AND NECK SURGERY
Exacerbation of inflammation following surgery has been shown to be associated 
with negative postoperative outcomes like pain (96), therefore the reduction of 
inflammation is a common target used by anesthesiologists to prevent postoperative 
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complications (97). Administration of GCs intravenously perioperatively is 
common after a wide variety of surgical procedures, including microvascular head 
and neck surgery. GCs are given to patients because they are believed to relieve 
postoperative pain, decrease swelling, prevent postoperative nausea and vomiting 
(PONV), and possible facilitate early discharge, although the evidence of benefit 
in postoperative use is contentious (6, 98-100). GC use became widespread in 
oral and maxillofacial surgery in the 1950s (101) and several studies have shown 
the benefits of GCs on recovery (6). Dexamethasone is one of the most common 
drugs administered by anesthesiologists and systemic dexamethasone has been 
shown to minimize postoperative nausea (PONV), pain, and post-extubation sore 
throat (7, 99, 102).
2.2.3 EFFECTS OF DEXAMETHASONE
2.2.3.1 Benefits
Nausea, vomiting, and retching complicate recovery from anesthesia frequently, 
occurring in more than 30% of patients (103). There are many studies on the 
benefits of dexamethasone and anesthesiologists favor its perioperative use widely 
to diminish PONV and pain (8, 98, 104-107). Episodes of PONV may cause many 
complications, like gastric aspiration, wound dehiscence, psychological distress, 
and delayed recovery (108). Particularly in reconstructive head and neck surgery, 
PONV may jeopardize the primary healing of the reconstructed area. GCs have 
been proven to reduce edema after different type of surgeries such as orthognathic 
surgery (109), ophthalmologic interventions (110), third-molar surgery (111), and 
neurosurgery (112). Dexamethasone has also been shown to improve the quality 
of postsurgical recovery after elective cardiac surgery (113).
2.2.3.2 Side-eects
GC use may lead to serious side-effects, even with short-term use (less than one 
week), and particularly with high doses. Studies have shown that the short-term use 
of GCs can cause increased risk for avascular osteonecrosis (114-116), GC induced 
psychosis (117-119), and increase of peptic ulcers and gastrointestinal bleeding 
(120). Dexamethasone slows down the inflammation process, which has various 
adverse effects on tissue healing and may disturb surgical wound healing and 
cause postoperative infections (121-123). Studies of the influence of perioperative 
dexamethasone on oncological surgery outcomes are scarce. Yu et al. reported 
the use of dexamethasone to be associated with decreased OS when investigating 
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the effect of perioperative administration of dexamethasone on 515 rectal cancer 
patients (124).
2.3 HEALTH RELATED QUALITY OF LIFE (HRQOL) WITH HNC
Anatomically demanding surgery causes significant morbidity, and this affects 
patients who experience significant impact on quality of life (125). HRQoL has 
become an important instrument to measure the outcome of patients, also with 
HNC. HRQoL after surgical or oncological treatment of HNC is well studied and 
there are many disease-specific and generic HRQoL questionnaires to measure 
the quality of life of cancer patients (4, 5, 126, 127). Previous studies have shown 
that advanced tumors, extensive surgical resection, free flap reconstruction and 
postoperative radiotherapy are associated with low HRQoL (128-130). 
The studies focusing on HRQoL after FFS for HNC patients are scarce and 
results contrary. Most of the studies report mild or moderate deterioration of 
global QoL. According to these studies, the acceptable level of global QoL was 
defined as comparable to population-based values (131-133). Some studies report 
QoL improved after FFS . Limitations of these studies include often short-term 
follow-up and variability in HRQoL instruments.
2.3.1 METHODS TO ASSESS QOL IN HCN
There have been different instruments to measure patients QoL available since 
the 1990s. Psychological well-being is individual and may vary greatly despite 
equal clinical outcome and treatment. Instruments can be generic or specific 
questionnaires and content of self-administrated questionnaires is variable 
(127, 134, 135). EORTC QLQ-H&N35 is one of the most commonly used specific 
questionnaire to measure QoL among HNC patients (136). It includes seven 
symptom scales and eleven single issues. Other HNC-specific questionnaires are, 
for example, UW-QoL and FACT-HN. Swallowing-specific QoL instrument MDADI 
(M.D. Anderson Dysphagia Inventory) is widely used with HNC patients (126, 
137). There is no consensus regarding which instrument is preferable, and disease-
specific instruments alone may not provide the most appropriate answers for this 
extremely challenging group of patients. 
The 15D questionnaire is designed in Finland for populations aged over 15 years. 
Use of 15D enables comparison of the HRQoL results with an age-standardized 
general population. It has been used in many cancer patient groups (138) including 
with HNC (139, 140). The 15D compares with other generic HRQoL instruments 
like the NHP, SF-20, SF-6D, and EQ-5D and a study by Richarson et al. ranked the 
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15D first among the most frequently used generic HRQoL instruments in sensitivity 
and construct validity in the area of cancer (141).
The 15 dimensions of the instruments are: moving, seeing, hearing, breathing, 
sleeping, eating, speech, excretion, usual activities, mental function, discomfort 
and symptoms, distress, depression, vitality, and sexual activity. The respondent 
chooses one of the five levels best describing his/her state of health at the time (the 
best level = 1; the worst level = 5) for each dimension. The 15D can be used as both 
a single index score measure and a profile measure. The single index number (15D 
score) ranges from 0 (dead) to 1 (full health) and the 15D score is calculated from 
the health state descriptive system (142). The change or difference of +/- 0.015 in 
the score is considered clinically important (143-146). 
2.4 MORTALITY AFTER RECONSTRUCTIVE HNC SURGERY
The complex anatomy and functions of the HNC region often lead to the need for 
reconstructive surgery. Postoperative problems may influence survival and high 
mortality is common despite advances in treatment. With an ageing population, 
HNC patients undergoing surgery are often older and tend to have comorbidities 
which can affect slowing the healing process and postoperative outcome. The 
presence of lymph node metastasis, invasion, tumor recurrence, postoperative 
complications, and advanced age have been described to be associated with 
worsened survival in some previous studies, but the results are contradictory (10, 
13, 14).
2.4.1 MORTALITY
The number of studies focusing on mortality after reconstructive surgery due to 
HNC is limited. Since FFS has been routinely used in HNC reconstruction globally, it 
is important to remember that something more serious than flap failure can happen 
postoperatively and to investigate what factors may associate with this. Even if the 
DSS has improved from 55% to 66% over the last decades (11, 12), five-year OS has 
been reported to be around 50–60% (9, 10). Previously published studies reveal 
that the five-year survival of HNC patients with microvascular reconstruction is 
lower (43–66%) than HNC patients in general (66%) (147, 148). 
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2.4.2 CAUSES OF DEATH
Causes of death of non-operated HNC survivors have been well described in both 
the short-term and long-term. Baxi et al., analyzed 35,958 non-metastatic head 
and neck squamous cell carcinoma (HNSCC) patients who survived at least 3 years 
from diagnosis and discovered that second primary malignancy (lung, esophagus, 
and colorectal cancer) was the leading cause of death, not the primary disease 
(149). Only a few earlier studies have focused on causes of death after FFS in HNC. 
Especially long-term results are limited. Tanaka et al. studied 1249 HNC patients 
treated with free flaps and found short-term (30-day) mortality to be 0.88% but 
long-term survival was not analyzed. The most common cause of death in one 
month was cerebral infarction (150). 
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3. AIMS OF THE STUDY
The aim of the present study was to investigate the prospectively collected group 
of patients with HNC and microvascular reconstruction. 
The specific aims were as follows: 
1.  To examine whether the perioperative use of dexamethasone in reconstructive
HNC surgery is beneficial for the patients.
2. To clarify whether the perioperative use of dexamethasone in HNC would
improve the quality and speed of patients’ recoveries and the effects on pain,
PONV, lactate levels, and need for insulin after microvascular surgery.
3. To evaluate the long-term HRQoL of HNC patients with microvascular
reconstruction compared to an age- and gender-standardized sample of the
general population.
4. To investigate whether perioperative dexamethasone influences short-term
mortality and to assess the causes of death and the predictors affecting long-
term mortality in reconstructive HNC patients.
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4. PATIENTS AND METHODS
This study consisted of a prospective, double-blind randomized group of 93 
HNC patients who had a microvascular reconstruction and were operated at the 
Department of Oral and Maxillofacial Surgery and Department of Plastic Surgery in 
Helsinki University Hospital, Finland between December 2008 and February 2013. 
In studies I, II, and IV the data was collected from randomized patients; in 
Study III, the data was collected from all patients independent of randomization.
4.1 ETHICAL CONSIDERATIONS
This study followed the Declaration of Helsinki for medical protocol and ethics 
and was approved by the regional Ethical Review Board of Helsinki University 
Central Hospital, Finland in 2008. The study was registered with EudraCT protocol 
(2008-000892-11). All patients signed a written informed consent form prior to 
randomization. 
4.2 OUTCOME VARIABLES
The main outcome variables were as follows:
Study I: Major complications, neck swelling, length of ICU and hospital stay, 
duration of intubation or tracheostomy and possible delay to the start of 
radiotherapy if needed.
Study II: Speed of recovery (ability to sit, stand, walk, drink fluids), pain, PONV, 
glucose balance, metabolic and inflammatory response.
Study III: Health-related quality of life (long-term).
Study IV: Mortality (short-term and long-term), causes of death
4.3 PREDICTOR VARIABLES
The primary predictor variable was the perioperative use of dexamethasone (studies 
I, II, and IV). Other predictor variables included in the analyses were: start of 
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using Heat and Moisture Exchanger (HME), time of drainage removal time, start 
of communication, sitting, standing, walking, drinking fluids, transferring to the 
hospital ward and home, the change in patients weight during hospital stay, age, 
sex, smoking, use of alcohol, Body Mass Index (BMI), history of alcohol use (major, 
moderate, or none), length of surgery, the ASA, Charlson Comorbidity Index (CCI), 
major complication, length of sedation (as duration of propofol infusion), opioid 
infusion, amount of pain medications, insulin, antiemetics and IV antibiotics, 
lactate and C-reactive protein (CRP)/Leukocyte levels (studies I-II). Alcohol use 
was defined as moderate if drinking was weekly or less, and major if it occurred 
daily. In all studies, the tumor classification, tumor site, type of reconstruction, 
possible postoperative radio/chemotherapy, and number of postoperative surgeries 
were analyzed. In study IV the primary (intermediate) cause of death was used 
in the analyses and possible tumor recurrence or metastasis were collected from 
patient records.
4.4 PATIENTS
Patients with HNC who underwent microvascular reconstruction were operated 
and included in the study between December 2008 and February 2013 at the 
Department of Oral and Maxillofacial Surgery and the Department of Plastic 
Surgery, Helsinki University Hospital, Finland. All patients were evaluated by 
the multidisciplinary head and neck tumor board of the Helsinki University 
Hospital. Altogether 110 patients participated in the study, 55 in each group, and 
10 were excluded. Exclusion criteria were peptic ulcer, history of liver or kidney 
dysfunction, glaucoma, psychosis from use of steroids, allergy to any constituent of 
the dexamethasone preparation used, and absence of written informed consent—97 
patients met the criteria. Four of these patients were later excluded, one because he 
was administered additional dexamethasone and three because of intraoperative 
cancellation of free flap reconstruction. Therefore, 93 patients were included in 
the study: 73 from the Department of Maxillofacial Surgery and 20 from the 
Department of Plastic Surgery. Patients were randomized into two groups: 51 
received dexamethasone (Oradexon®, DEX), and 42 were controls (NON-DEX) 
(Figure 1). Discrepancy in the size of the two groups is explained by the effect of 
luck of random selection. A total dose of 60 mg of dexamethasone was administered 
to patients in the DEX group intravenously over three days peri- and postoperatively 
(10 mg every 8 hours on the first day, every 12 hours on the second day, and one dose 
on the third day). The group information was provided in a sealed envelope to the 
anesthesiologist in charge of the anesthesia of the surgery and the anesthesiologist 
administered all doses to the patient, surgeons were unaware of which group the 
patients were assigned. 
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Figure 1. Patient selection (Study I, II, and IV)
4.4.1 PATIENTS POSTOPERATIVE CARE 
Patients received standard, balanced anesthesia with continuous infusion of 
propofol and alfentanil. After the operation in the ICU, sedation was discontinued, 
and the patient was weaned from the respirator. The vitality of the microvascular 
flap was verified regularly. CRP, leukocyte count and lactate levels were measured 
for five days postoperatively. The targeted glucose level was 5–8 mmol/l and 
maintained with insulin infusion; insulin consumption and the total daily amount 
of insulin was registered. Free flaps were monitored with clinical examination, 
through visualization and checking the vital signs of the flap with pinprick tests 
every hour on the first postoperative day, and every two to four hours after that 
during the first three days. 
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4.4.2 MEDICATIONS AND FOLLOW-UP
Patients received antibiotics; cefuroxime 1.5 g x 3 IV and metronidazole 500 mg 1 x 
3 IV over an average of 7 days, starting on induction of general anesthesia. Allergic 
patients received clindamycin 300 mg x 4 IV. Pain was measured using a 10-cm 
Visual Analog Scale (VAS) pain scores from 0 to 10 (0 indicating no pain and 10 
indicating maximum pain). VAS was always measured before pain medication was 
administered. Patients were given paracetamol 1g x 3 IV, or oxycodone 0.2–0.4 
mg/10kg IV, as a pain medication in the postoperative period if the patients scored 
more than 4 on a VAS, or when requested. No non-steroidal-anti-inflammatory 
analgesics were given. Nausea was treated with ondansetron 4 mg IV when 
needed. The data was collected and sorted from the follow up forms and hospital 
database by one physician (SK). Patients neck swelling was measured daily from 
the highest and marked point for 7 days postoperatively and the highest increase 
in the neck circumference (cm) in comparison to preoperative circumference was 
used for analysis. Patient rehabilitation (ability to sit, stand, walk, drink fluids) was 
recorded and patients were followed for 30 days after surgery for any surgical or 
medical complications. Surgical complications were classified according to Dindo 
et al. so that all the major complications were included to the complication group 
(IIIb) or worse and needed secondary surgery within three weeks (84, 85). Minor 
complications included local bed-side treatment and no need for further surgical 
interventions in the operation room. 
4.4.3 HEALTH RELATED QUALITY OF LIFE (STUDY III)
HRQoL of the patients was measured with the multidimensional, generic 15D 
instrument (15D) (Appendix). The 15D data for the general population came from 
the representative National Health 2011 Survey and for best comparison, those 
individuals were selected from the Helsinki University Hospital catchment area, 
and were in the same age range as the patients (n=1148). This sample reflected 
the age and gender distribution of the patients. All patients filled in the baseline 
15D questionnaire before surgery and follow-up questionnaires were sent to all 
patients alive in a prepaid, pre-addressed envelope in October 2016. All patients 
who answered the follow-up questionnaire were included in the analysis and 
HRQoL was studied regardless of patient group. The influence of tumor site, use 
of microvascular reconstruction, tumor stage, and postoperative RT on long-term 
HRQoL were investigated. 
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4.4.4 MORTALITY (STUDY IV)
Causes of death for deceased patients were obtained from Statistics Finland and 
patients were followed up until the end of the year 2017. The primary cause of 
death (intermediate) was used in the analysis and causes of death were divided 
into three categories: HNC, non-HNC (other cancer than HNC), and other cause 
of death (cardiovascular, liver cirrhosis). Additional variables were collected from 
patient records including data of patients’ free flap type, tumor location and stage, 
BMI, alcohol use, smoking, ASA, CCI, possible postoperative RT or chemotherapy, 
number of complications, number of surgeries, and possible tumor recurrence or 
metastasis. Factors associated with mortality were studied during the long-term 
follow-up.
4.5 STATISTICS
Descriptive statistics were reported as means and standard deviations (SD), 
medians or percentages. SPSS software was used for analyses in Studies I to IV 
and R 3.6.1 software was used for Study IV (R Core Team, 2019. R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria) (151). The significance of associations between groups and 
variables were evaluated by T-tests and Wilcoxon two-sample tests, Chi-square 
tests (Studies I–IV), or ANOVA were performed (Study III–IV). Risk ratios (RRs) 
with 95% confidence intervals were calculated to analyze the risk of outcomes in 
Studies I, II, and IV. Differences in mean values between groups and continuous 
variables were assessed by logistic regression and multivariate linear regression 
analysis was performed (Studies I, II, and IV). Kaplan-Meyer plot was used to 
compare the survival of the patients in the two study groups and variables for 
the multivariate model were selected using variables that were significant in the 
univariate model and/or have clinical relevance, and least absolute shrinkage and 
selection operator (Study IV) (152). Results from logistic regression analyses were 
reported as odds ratios (OR), and results from Cox’s proportional hazard models 
as hazard ratios (HR). Power analysis to determine the number of patients needed 
was performed on the original material.
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5. RESULTS
5.1 PERIOPERATIVE DEXAMETHASONE AND COMPLICATIONS 
IN HNC PATIENTS WITH MICROVASCULAR 
RECONSTRUCTION (STUDY I)
There were no major statistical differences between the groups regarding 
preoperative demographic data, except there were more major alcohol users in 
the NON-DEX group (DEX n = 8 (16%), NON-DEX n = 13 (31%), p=0.038 and 
more tracheostomized patients (60% vs 33%, p=0.034). Demographic statistics 
of the 93 patients and surgical data are shown in Table 3 and Table 4. Patients 
TNM classification is presented in Table 5.
There were significantly more major complications (need for second surgery 
in general anesthesia within three weeks), especially surgical infections (DEX 
27% vs NON-DEX 7%), during the postoperative period in patients receiving 
dexamethasone (p=0.012) (Table 6). 
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Table 3. Demographic data of the patients (Study I–IV)* 
Demographic 
characteristics and 
comorbidities
All (n=93) DEX (n=51) NON-DEX (n=42) p
Age (years) 65 (34–93) 65 (39–93) 65 (34–88) 0.798
Male/Female 59/34 32/19 27/15 0.878
BMI 24.9 (15.8–42.7) 25.5 (15.8–42.7) 24.5 (17.0–32.6) 0.331
ASA (1/2/3/4) 6/23/48/13 3/10/27/11 3/13/21/4 0.339
History of alcohol use 
(major/moderate/no)
21/45/27 8/23/20 13/22/7 0.038
History of smoking (yes/no) 37/56 19/32 18/24 0.583
CCI (0–1/2–4/5–9) 49/29/15 24/19/8 25/10/7 0.363
Diabetes 15/93 (18%) 11/51 (22%) 4/42 (10%) 0.116
Preoperative characteristics
Previous radiotherapy 9/93 (10%) 5 (10%) 4 (10%) 0.939
Previous chemotherapy 3/93 (3%) 1/51 (2%) 2/42 (5%) 0.447
Previous operation 
in same area
14/91 (15%) 10/49 (20%) 4/42 (10%) 0.151
Perioperative data
Tracheostomy / intubation 47 (51%)/46 (49%) 21 (41%)/30 (59%) 26 (62%)/16 (34%) 0.047
Postoperative data
Radiation therapy 
postoperatively
45 (50%) 20 (43%) 25 (58%) 0.211
Chemotherapy 
postoperatively 
20 (23%) 8 (17%) 12 (29%) 0.326
*Data presented here with the permission of the copyright holders. (153)
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Table 4. Surgical data of the patients (Study I–IV)*
  All  (n=93)
DEX  
(n=51)
NON-DEX 
(n=42) p
Primary lesion
Tongue 27 13 14
Floor of mouth 11 8 3
Mandible 26 14 12
Maxilla 15 9 6
Buccal mucosa 9 5 4
Tonsil 3 1 2
Palate 1 1 0
Larynx - hypofarynx 1 0 1
Reconstruction type: Soft tissue / bone ** 83/10 46/5 37/5 0.745
Flap type 0.360
Forearm flap 51 31 20
ALT 33 15 18
DCIA 4 2 2
Fibula 1 1 0
LD 1 0 1
Scapula + LD 2 0 2
Scapula + parascapula 1 1 0
Neck dissection 0.207
Unilateral 78 45 33
Bilateral 15 6 9
Sentinel 10 7 3
Neck dissection levels 0.201
L1-3 28 18 10
L1 - 4/5 or radical 55 26 29
Operation time (min) 340 (87–975) 340 (138–975) 359 (208–719) 0.373
DEX=dexamethasone group; NON-DEX=non-dexamethasone group; ALT=Anterolateral Thigh Perforator 
flap; LD=latissimus dorsi muscle; DCIA=The deep circumflex iliac artery bone flap; CCI=Charlson 
Comorbidity Index.
Alcohol use was defined as moderate if drinking was weekly or less and major if it occurred daily. 
Patients were defined as smokers if they smoked before surgery. Data given as median and range.
*Data presented here with the permission of the copyright holders. (153)
**Free flaps including both soft-tissue and bone are classified as bone reconstructions.
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Table 5. TNM classification of the patients (Study I–IV)* 
N0 N1 N2A-C TOTAL
DEX NON-DEX DEX NON-DEX DEX NON-DEX
T1–T2 22 12 2 6 3 6 51
T3–T4A-B 12 10 2 1 9 6 40
TOTAL 34 22 4 7 12 12 91
% of n 68 % 54 % 8 % 17 % 24 % 29 %
DEX=dexamethasone group; NON-DEX=non-dexamethasone group. 
*Data presented here with the permission of the copyright holders. (153)
Table 6. Major complications of the patients (Study I–IV) 
ALL  
(n=93)
DEX  
(n=51)
NON-DEX 
(n=42) p
Number of major complications (patients) 17/93 (18%) 14/51 (27%) 3/42 (7%) 0.012*
Number of major complications 20 16 4
Venous thrombosis of the flap 6 (6%) 4 (8%) 2 (5%)
Flap loss 3 (3%) 2 (4%) 1 (2%)
Wound necrosis, fistula, infection 4 (4%) 4 (8%) 0
Postoperative bleeding 1 (1%) 1 (2%) 0
Later tracheostomy 5 (4%) 4 (8%) 1 (2%)
Pneumothorax 1 (1%) 1 (2%) 0
Number of minor complications (patients) 7/93 (11%) 4/51 (10%) 3/42 (12%) 0.899
Fluid collection/seroma 2 (2%) 1 (2%) 1 (2%)
Local wound infection (neck or face) 1 (1%) 1 (2%) 0
Hematoma/bleeding 3 (3%) 1 (2%) 2 (5%)
Fistula 1 (1%) 1 (2%) 0
Infection postoperatively 17/94 (18%) 10/51 (20%) 7/42 (17%) 0.715
DEX=dexamethasone group; NON-DEX=non-dexamethasone group. Data given as median and range.
*Data presented here with the permission of the copyright holders. (153)
No statistical differences existed between the groups for any of the main primary 
outcome variables, which were neck swelling, length of ICU stay, and hospital 
stay, duration of intubation or tracheostomy, and delay to the start of possible 
radiotherapy. (Table 7). Patients who received dexamethasone did not have a 
shorter treatment period in the ICU or ward nor was the tracheostomy or intubation 
time shorter.
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Table 7. Primary outcome measures (Study I) 
All  
(n=93)
DEX  
(n=51)
NON-DEX 
(n=42) p
Neck swelling (cm) (n=77) ** 5.5 (0–13) 5.0 (0–12.5) 6.0 (1.5–13) 0.196
Length of ICU stay (days) (n=93) 3 (1–12) 3 (1–12) 3 (1–8) 0.965
Length of hospital stay (days) (n=91) 13 (5–49) 12 (5–35) 13 (6–49) 0.594
Duration of tracheostomy (days) (n=46) 8 (2–43) 6 (2–18) 9 (2–42) 0.251
Duration of intubation (days) (n=47) 1 (0–6) 1 (1–6) 1 (0–5) 0.064
Start of postoperative radiation 
therapy (days) (n=33) 43 (30–99) 47 (34–99) 43 (30–74) 0.110
DEX=dexamethasone group; NON-DEX=non-dexamethasone group. Data given as median and range.
*Data presented here with the permission of the copyright holders. (153)
** Highest increase (cm) in neck circumference during the seven postoperative days
5.2 EFFECT OF DEXAMETHASONE ON RECOVERY FOLLOWING 
SURGERY OF HNC PATIENTS WITH MICROVASCULAR 
RECONSTRUCTION (STUDY II)
5.2.1 RECOVERY
There were no differences between the groups in parameters of postoperative 
mobilization, ability to drink fluids after surgery, or in other clinical measures of 
recovery.
5.2.2 PAIN
There was significantly less pain in the study group (p=0.030) and the total 
oxycodone dose over 5 days postoperatively was significantly lower as compared 
with the control group (p=0.040), especially during the first postoperative day 
(Figure 2). 
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Days from surgery
Figure 2. VAS area under the curve after FFS. Data are presented as means with 95% confidence limits. 
DEX=dexamethasone group; NON-DEX=control group; VAS=Visual analog scale (published in Study II).
5.2.3 PONV
Dexamethasone did not significantly reduce PONV over 5 days postoperatively 
(p>0.05). There was a statistical difference in nausea in the second postoperative 
day (p=0.0264), but the clinical difference was not significant, because the need 
for antiemetics was low in both groups. 
5.2.4 GLUCOSE BALANCE
Patients receiving dexamethasone required significantly more insulin when 
compared with patients in the control group (p<0.001) as presented in Figure 3. 
Table 8 summarizes the most significant outcomes of Study II. 
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Figure 3. Insulin area under the curve after microvascular reconstruction. Data are presented as means 
with 95% confidence limits. DEX: dexamethasone group (blue line), NON-DEX: control group (red dashed 
line), IU: international units of insulin (published in Study II).
Table 8. Patients postoperative results of Study II (Modified from Study II)
All  
(n=93)
DEX  
(n=51)
NON-DEX  
(n=42) p
Length of ICU stay (days) 3 (1–12) 3 (1–12) 3 (1–8) 0.965
Length of hospital stay (days) 
(n=91) 13 (5–49) 12 (5–35) 13 (6–49) 0.594
Length of sedation infusion 
(days) 2 (0–6) 2 (1–6) 1 (0–6) 0.088
Length of opioid infusion (days) 1 (0–4) 1 (0–3) 1 (0–4) 0.497
Total dose of oxycodone in 
5 days (mg) 95.2 81.2 112.1 0.040*
Total dose of ondansetron in 
5 days (mg) 83 (mean 0.89) 34 (mean 0.67) 49 (mean 1.17) 0.058
Length of IV antibiotics (days) 7 (3–30) 8 (3–30) 7 (3–22) 0.209
Able to sit (days) 2 (1–6) 2 (1–6) 2 (1–6) 0.5174
Able to stand (days) 2 (1–7) 2 (1–6) 2(1–7) 0.537
Able to walk (days) 3 (1–12) 3 (1–12) 3 (1–10) 0.784
Able to drink fluids (days) 4 (1–19) 3 (1–19) 5 (1–17) 0.171
DEX=dexamethasone group; NON-DEX=non-dexamethasone group. Data given as median and range.
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5.2.5 METABOLIC AND INFLAMMATORY RESPONSE 
Lactate and leukocyte levels were significantly higher (p<0.001) during the first 
five postoperative days in the DEX group. CRP levels were significantly lower 
(p<0.001) and leukocyte counts were significantly higher (p<0.001) in patients 
receiving dexamethasone. 
5.3 LONG-TERM QUALITY OF LIFE (STUDY III) 
All patients were considered as a one group. The median time between surgery and 
HRQoL assessment was 4.9 years (range 3.7–7.8). Of the 93 patients, 61 (66%) 
were alive by the end of the follow-up (December 2016) and the number of patients 
who answered the long-term follow-up questionnaire was 42 (69%) (Figure 4). 
The mean 15D score of all patients (n=42) at the 4.9-years follow-up point was 
significantly lower than at baseline (p=0.010) (Figure 5). Figure 6 shows the 
preoperative mean dimensions relative to the general population. The dimensions 
of “speech” and “usual activities” were significantly impaired at the end of the 
follow-up (Figure 7). There was a significant difference at the 4.9-years follow-
up between patients and the general population in the mean 15D score (patients 
0.844 vs population 0.894, p=0.014). After the 4.9-years follow-up, patients were 
significantly (p<0.05) worse off in the dimensions of “speech”, “eating”, and “usual 
activities”. 
Figure 4. Flow chart of the patients (Study III)
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Figure 5. Mean 15D profiles of HNC patients with microvascular reconstruction (n=42) at baseline and 
4.9 years after operation (Published in Study III).
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Figure 6. 15D profiles of HNC patients with microvascular reconstruction (n=42) at baseline compared 
with age- and gender-matched general population (Published in Study III).
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Figure 7. 15D profiles of HNC patients with microvascular reconstruction (n=42) at follow-up compared 
with age- and gender-matched general population (Published in Study III).
5.4 MORTALITY AND SURVIVAL (STUDY IV)
5.4.1. DEMOGRAPHIC DATA
None of the patients had radiologically diagnosed distant metastasis or locoregional 
recurrence preoperatively. Second primary HNC occurred in 16 patients of all (17%, 
diagnosis made between 32-3363 days, median 612). Locoregional metastasis on 
the neck occurred in 13 patients (14%, diagnosis made between 52-1982 days, 
median 600) and distant metastasis in 13 patients (14%, diagnosis made between 
32-1982 days, median 244) during follow-up. Four patients developed other cancer 
than HNC during follow-up. 
5.4.2 SHORT-TERM MORTALITY
There were two deceased patients within 33 days; both in the DEX group. There 
were significantly more deaths in the DEX group during the first six months (DEX 
n=7, NON-DEX n=0) and one year (DEX n=11, NON-DEX n=2, Chi-square test 
p=0.043) after surgery (Figure 8). Five out of seven (71%) patients in the DEX 
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group that died during the first 6 months, experienced postoperative complications 
(2 numerous operations due to rapid spread of cancer, 1 pneumonia, 1 local 
infection, 1 venous thrombosis). The primary cause of death was HNC for all 
deceased patients during the first 12 postoperative months.
Figure 8. Number of deceased patients (n=38) between groups during the follow-up (modified from 
Study IV). DEX=dexamethasone group; NON-DEX=non-dexamethasone group; N/A: Statistical methods 
not available.
5.4.3 LONG-TERM MORTALITY
The median follow-up time was 5.3 years (range 33 days–9 years). Altogether 38 
patients (41%) had died during the follow-up by the end of 2017. Locoregional 
metastasis occurred in 9 patients (24%, p=0.025) and distant metastasis in 12 
patients (32%, p<0.001) of all the 38 deceased patients in the follow-up (p=0.025). 
In the long-term follow-up, deceased were more likely to have had more advanced 
decease (higher T classification, p=0.002; and higher stage, p=0.008), need 
for gastrostoma (p=0.002), received more often postoperative chemotherapy 
(p=0.005), and more often locoregional (p=0.025) or distal metastases (P<0.001) 
in the follow-up (Table 9). Five patients (13%) survived beyond five years but died 
later (latest 7.6 years after the operation).
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Table 9. Comparison of study variables and survival data in follow-up (median 5.3 years) (Modified from Study IV)
Survived  
(N=55)
Deceased 
(N=38)
Total  
(N=93) p value
Group (n, %) 0.2591
DEX 27 (49.1) 24 (63.2) 51 (54.8)
NON-DEX 28 (50.9) 14 (36.8) 42 (45.2)
Gender (n, %) 0.6281
Female 19 (34.5) 15 (39.5) 34 (36.6)
Male 36 (65.5) 23 (60.5) 59 (63.4)
BMI § 0.2842
Median (Range) 24.7 (16.0–39.4) 25.6 (15.8–42.7) 24.9 (15.8–42.7)
ASA (n, %) 0.6211
1 5 (9.1) 1 (2.6) 6 (6.5)
2 14 (25.5) 9 (23.7) 23 (24.7)
3 28 (50.9) 21 (55.3) 49 (52.7)
4 8 (14.5) 7 (18.4) 15 (16.1)
History of alcohol use (n, %) §§ 0.1371
Major 13 (23.6) 8 (21.6) 21 (22.8)
Moderate 30 (54.5) 14 (37.8) 44 (47.8)
No 12 (21.8) 15 (40.5) 27 (29.3)
History of smoking (n, %) † 0.7041
Yes 21 (38.2) 16 (42.1) 37 (39.8)
No 34 (61.8) 22 (57.9) 56 (60.2)
CCI (n, %) 0.0821
0–1 32 (58.2) 17 (44.7) 49 (52.7)
2–4 18 (32.7) 11 (28.9) 29 (31.2)
5–9 5 (9.1) 10 (26.3) 15 (16.1)
Median age at operation (years, range) 64.7 (39.2–87.7) 66.0 (34.2–92.8) 65.2 (34.2–92.8) 0.5222
Airway access for mechanical ventilation (n, %) 0.2381
Intubation 30 (54.5) 16 (42.1) 46 (49.5)
Tracheostomy 25 (45.5) 22 (57.9) 47 (50.5)
PEG (n, %) 0.0021
Yes 19 (34.5) 23 (60.5) 42 (45.2)
No 34 (61.8) 10 (26.3) 44 (47.3)
Later 2 (3.6) 5 (13.2) 7 (7.5)
Reconstruction type (n, %) 0.5341
Bone 5 (9.1) 5 (13.2) 10 (10.8)
Soft tissue 50 (90.9) 33 (86.8) 83 (89.2)
Site of the primary lesion (n, %) 0.4281
Maxilla 8 (14.5) 7 (18.4) 15 (16.1)
Mandible 11 (20.0) 15 (39.5) 26 (28.0)
Tongue 17 (30.9) 10 (26.3) 27 (29.0)
Floor of mouth 8 (14.5) 3 (7.9) 11 (11.8)
Buccal mucosa  7 (12.7) 2 (5.3) 9 (9.7)
Tonsil 2 (3.6) 1 (2.6) 3 (3.2)
Palate 1 (1.8) 0 (0.0) 1 (1.1)
Larynx - hypopharynx 1 (1.8) 0 (0.0) 1 (1.1)
Flap type (n, %) 0.0531
ALT 17 (30.9) 15 (39.5) 32 (34.4)
Forearm flap 35 (63.6) 16 (42.1) 51 (54.8)
Other †† 3 (5.5) 7 (18.4) 10 (10.8)
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Neck dissection (n, %) 0.2831
Unilateral 48 (87.3) 30 (78.9) 78 (83.9)
Bilateral 7 (12.7) 8 (21.1) 15 (16.1)
Neck dissection levels (n, %) 0.5061
Sentinel node biopsy 6 (10.9) 4 (10.5) 10 (10.8)
1–3 19 (34.5) 9 (23.7) 28 (30.1)
1–4/5 or radical 30 (54.5) 25 (65.8) 55 (59.1)
pT‡ (Mean (SD)) 2.07 (1.36) 2.97 (1.21) 2.44 (1.37) 0.0023
Stage (n, %) ‡‡ 0.0081
1 24 (43.6) 4 (10.8) 28 (30.4)
2 4 (7.3) 3 (8.1) 7 (7.6)
3 5 (9.1) 4 (10.8) 9 (9.8)
4 22 (40.0) 26 (70.3) 48 (52.2)
Radiation therapy postoperatively (n, %) 0.0761
No 32 (58.2) 15 (39.5) 47 (50.5)
Yes 23 (41.8) 23 (60.5) 46 (49.5)
Chemotherapy postoperatively (n, %) # 0.0051
No 47 (85.5) 22 (59.5) 69 (75.0)
Yes 8 (14.5) 15 (40.5) 23 (25.0)
Major complication (n, %) 0.0961
No 48 (87.3) 28 (73.7) 76 (81.7)
Yes 7 (12.7) 10 (26.3) 17 (18.3)
Second primary in follow-up (n, %) 0.4141
No 47 (85.5) 30 (78.9) 77 (82.8)
Yes 8 (14.5) 8 (21.1) 16 (17.2)
Distant metastasis in follow-up (n, %) <0.0011
No 54 (98.2) 26 (68.4) 80 (86.0)
Yes 1 (1.8) 12 (31.6) 13 (14.0)
Locoregional metastasis in follow-up (n, %) 0.0251
No 51 (92.7) 29 (76.3) 80 (86.0)
Yes 4 (7.3) 9 (23.7) 13 (14.0)
DEX: Dexamethasone group
NON-DEX: Non-dexamethasone group
N: Number
BMI: Body Mass Index
ASA: American Society of Anesthesiologists
CCI: Charlson Comorbidity Index
PEG: Percutaneous endoscopic gastrotomy
§ Data are missing from one patient
§§ Alcohol use was defined as moderate if drinking was weekly or less and major if it occurred daily, data are 
missing from two patients
† Patients were defined as smokers if they smoked before surgery
ALT: Anterolateral Thigh Perforator flap
†† Other: 4 DCIA (the deep circumflex iliac artery bone flap), 1 fibular flap, 1 LD (Latissimus dorsi muscle flap), 2 
Scapular + LD flap and 1 Scapular + parascapular flap
‡ pT=Pathological tumor classification, data are missing from two patients
‡‡ Data are missing from two patients
# Data are missing from two patients
p < 0.05 (significant)
1: Pearson’s Chi-squared test
2: Kruskal-Wallis rank sum test
3: Linear Model ANOVA (Mann-Whitney with two groups)
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Altogether 32 patients had died within five years, therefore the 5-year OS for all patients 
(n=93) was 65.6%. OS for all patients for the whole follow-up period (median 5.3 years) was 
59% (55/93). Even though there were more deaths in DEX groups during the whole follow-
up period, according to the Kaplan-Meier curve and log-rank test, there was no statistically 
significant difference in long-term survival between the treatment groups (Figure 9).
Figure 9. Survival curves. There was 24 events (hazard=0.115) in DEX group, and 14 events (hazard=0.0673) in 
NON-DEX group. Log-rank statistic was 0.094 for the whole follow-up, and 0.019 after 12 months.
For an initial multivariate Cox model, we identified 13 confounders. After adjustment, 
contrary to the univariate analysis, the use of dexamethasone predicted excess risk of 
mortality (p=0.004). Also, the reduced model suggests, that the other statistically significant 
long-term predictors of death and poor OS during follow-up were CCI 5–9 and presence 
of distant metastasis (Table 10).
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Table 10. Factors a³ecting long-term mortality in follow-up (5.3 years) (modified from Study IV)
OVERALL SURVIVAL ALL HR (multivariable) HR (multivariable reduced)
Group DEX 51 - -
NON-DEX 42 0.22 (0.09–0.56, p=0.001) 0.31 (0.14–0.69, p=0.004)
pT § 1 38 - -
2 15 3.07 (0.77–12.26, p=0.111) 2.58 (0.74–9.03, p=0.137)
3 3 5.16 (0.83–32.00, p=0.078) 3.13 (0.56–17.59, p=0.196)
4 37 4.22 (1.47–12.09, p=0.007) 2.56 (0.98–6.71, p=0.055)
PEG Yes 42 - -
No 44 0.22 (0.06–0.74, p=0.015) 0.37 (0.14–1.04, p=0.059)
Later 7 2.74 (0.61–12.34, p=0.188) 2.09 (0.58–7.51, p=0.256)
Major complication (n) No 76 - -
Yes 17 0.94 (0.30–2.90, p=0.910) 1.59 (0.65–3.89, p=0.312)
CCI 0–1 49 - -
2–4 29 3.79 (1.14–12.59, p=0.029) 1.57 (0.64–3.83, p=0.322)
5–9 15 7.29 (2.33–22.83, p=0.001) 5.82 (2.26–14.98, p<0.001)
History of alcohol use (n) §§ Major 22 - -
Moderate 44 0.81 (0.26–2.51, p=0.721) 0.84 (0.32–2.18, p=0.722)
No 27 2.35 (0.74–7.45, p=0.146) 1.53 (0.54–4.34, p=0.421)
Radiation therapy  
postoperatively (n) No 47 - -
Yes 46 0.83 (0.27–2.59, p=0.752) -
Age at operation Mean (SD)
65.3 
(11.0) 1.00 (0.96–1.05, p=0.848) -
Gender (n) Female 34 - -
Male 59 0.72 (0.28–1.80, p=0.478) -
BMI Mean (SD)
25.6 
(4.9) 1.05 (0.96–1.14, p=0.277) -
Second primary in  
follow-up (n) No 77 - -
Yes 16 0.51 (0.14–1.77, p=0.286) -
Distant metastasis in  
follow-up (n) No 80 - -
Yes 13 16.10 (5.13–50.52, p<0.001) 10.41 (3.99–27.13, p<0.001)
Locoregional metastasis in 
follow-up (n) No 80 - -
Yes 13 2.82 (1.00–7.94, p=0.050) -
Chemotherapy  
postoperatively (n) # No 69 - -
Yes 23 1.83 (0.51–6.54, p=0.352) -
DEX: Dexamethasone group
NON-DEX: Non-dexamethasone group
N = number
§ pT=Pathological tumor classification, data are missing from one patient
CCI: Charlson Comorbidity Index
§§ Alcohol use was defined as moderate if drinking was weekly or less and major if it occurred daily, data are 
missing from two patients
BMI: Body Mass Index
# Data are missing from two patients
46
5. Results
5.4.4 CAUSES OF DEATH
The primary cause of death was HNC for most of the deceased patients (30/38, 
79%). The primary cause of death was HNC in all patients who died during the first 
6 months (n=7, 18,4%) as well as during the 6–12 months (n=13, 34.2%). Three 
patients died because of another cancer (one prostate cancer, one colon cancer, 
and one bladder cancer). Five patients died for other causes (four cardiovascular 
disease, one alcoholic liver cirrhosis). Causes of death and time for all the patients 
can be seen in Table 11.
Table 11. Causes of death for 38 deceased patients
ALL  
(n = 93)
DEX  
(n = 51)
NON-DEX  
(n = 42) P
Primary cause  
of death, n
Number, n (%)
< 33 days 2 (2) 2 (4) 0
< 6 months 7 (18) 7 (16) 0 HNC (7)
< 12 months 13 (34) 11 (28) 2 (6) 0.043* HNC (13)
5 years 31 (61) 20 (39) 12 (29) 0.259
During follow-up 38 (41) 24 (47) 14 (33) 0.180
Primary cause of death
HNC 28 (74) 19 (80) 11 (79) 0.415
Non-HNC 3 (8) 1 (4) 2 (14)
Other cause of death** 5 (13) 4 (17) 1 (7)
DEX=dexamethasone group; NON-DEX=non-dexamethasone group; HNC=Head and neck cancer.
*p<0.05 (significant)
**1 Liver cirrhosis, 4 cardiovascular disease
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6. DISCUSSION
6.1 METHODOLOGICAL CONSIDERATIONS
This is the first prospective, double-blind randomized controlled trial to study 
whether perioperative use of dexamethasone in reconstructive HNC surgery is 
beneficial for the patients. As in many other fields of surgery, in reconstructive 
surgery perioperative GCs are widely used to treat patients because they are believed 
to reduce pain, PONV, and the risk of immediate complications, like prolonged 
intubation and sedation; they are also considered to prevent edema in the area 
of anastomosis, which can lead to possible flap loss, and thus improve recovery. 
Patients benefit by experiencing recovery without complications. Prolonged 
periods of treatment often cause postoperative problems like delay of possible 
adjuvant oncological treatments. This thesis reports the significant findings of the 
perioperative use of GCs, long-term HRQoL, and mortality of HNC patients with 
microvascular reconstruction.
6.2 USE OF GLUCOCORTICOIDS IN ASSOCIATION WITH 
RECONSTRUCTIVE HNC SURGERY
6.2.1 COMPLICATIONS AND INFLUENCE OF DEXAMETHASONE
The findings of the present study revealed that major complications occurred 
significantly more frequently in patients administered GCs than in the control group 
(153, 154). In addition, all infections that needed surgical interventions occurred 
only in patients receiving dexamethasone, and none in the control group. There is 
previous evidence of contradictory results regarding the influence of perioperative 
GCs on postoperative complications and infections (123, 155). In the study of Percival 
et al., the authors concluded that intraoperative administration of dexamethasone 
for anti-emetic purposes may confer an increased risk of postoperative infection 
(121). The operations in the analysis included orthopedic, thoracic, neurosurgical, 
ENT, vascular, urology, plastic, breast, colonic, and gastroenterological procedures 
but the amounts of dexamethasone were relatively small. The study of Mastropietro 
et al. (121) was the first to publish an association between infection and increased 
cumulative duration of GC after pediatric cardiac surgery. The authors reviewed 
the files of 76 children, all of whom had received postoperative hydrocortisone. 
Altogether 86% of the children received perioperative dexamethasone and 36% of 
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the children had postoperative infections that were significantly associated with GC 
exposure (122). There are no previously published publications of the association 
with GC use and reconstructive HNC surgery.
6.2.2 RECOVERY 
The current study demonstrated that the use of dexamethasone had little effect 
on immediate postoperative recovery. Before this study, all reconstructive HNC 
patients received perioperative dexamethasone in Helsinki University Hospital, 
Finland and it was expected that it would decrease edema in the neck area, which 
would hasten recovery. In this study, the use of dexamethasone did not shorten the 
operation time nor the duration of tracheostomy, intubation, or sedation. Similarly, 
dexamethasone did not shorten either the length of ICU or hospital stay, nor 
hasten the ability to sit, stand, walk, and drink fluids. There was no effect on the 
delay of starting adjuvant radiotherapy within the patient groups. Furthermore, 
the use of dexamethasone did not accelerate the recovery process. This is in line 
with Jean et al. who made a systematic review and meta-analysis of the effects of 
perioperative systemic GCs in patients undergoing orthognathic surgery and found 
no beneficial evidence for the length of the hospital stay (156). 
6.2.3 PAIN
There are many publications in different fields of surgery that describe the 
perioperative use of GCs to reduce pain (104, 106, 107). This was the only benefit 
of the use of GCs with HNC patients in the current study. Although patients in the 
DEX group reported significantly less pain and needed less oxycodone during the 
five postoperative days, the routine use of dexamethasone is not justified in this 
patient group, because it causes other disadvantages. This finding is in line with 
Afman et al., who made a meta-analysis of eight randomized trials testing the use 
of dexamethasone to reduce post-tonsillectomy pain for pediatric patients and 
concluded that dexamethasone may reduce pain, but consideration of routine use 
seems reasonable because of the adverse side-effects (157). Clayburgh et al. showed 
in their randomized, controlled study of HNC patients undergoing transoral robotic 
surgery, that extended perioperative GC use may decrease the length of hospital 
stay, although there was no significant difference in pain measured between the 
groups (158).
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6.2.4 PONV
Dexamethasone is often used by anesthesiologists to reduce the risk of PONV 
in surgical patients. In the current study, perioperative dexamethasone failed to 
significantly reduce PONV in five days postoperatively. A similar phenomenon 
was observed in studies by Jahromi et al., and also Furst et al. (159, 160). Wattwil 
et al. studied PONV following breast surgery and assessed that ondansetron or 
dexamethasone are equally effective in the prevention of PONV (161). Haapanen 
et al. investigated the effect of dexamethasone on PONV in 119 facial fracture 
patients in their prospective, randomized study and concluded that the difference 
of PONV between the groups was only minor thus alternative medications should 
be used for prevention of PONV in this patient group (162).
6.2.5 GLUCOSE BALANCE AND METABOLIC / INFLAMMATORY RESPONSE
Patients required significantly more insulin in the DEX group in the current study. 
Dieleman et al. showed in their multicenter, randomized, double-blind, placebo-
controlled trial of 4494 patients undergoing cardiac surgery with cardiopulmonary 
bypass that dexamethasone was associated with higher postoperative glucose levels 
and the use of dexamethasone did not benefit the patients (163). Surgery causes 
changes in blood count. Ottens et al. showed in their randomized controlled trial 
of 498 patients that the administration of intraoperative high-dose dexamethasone 
was associated with significantly higher postoperative lactate and glucose levels 
after cardiac surgery (164). It is well known that GCs reduce the systemic 
inflammatory response caused by surgical trauma. Use of GCs is associated with 
postoperative leukocytosis and lower CRP levels (165-167). Postoperative leukocyte 
and CRP concentrations have been found to be useful markers of the magnitude 
of the operative injury (168, 169). Also, in the current material, CRP levels were 
significantly lower, and leukocyte count significantly higher as was expected in 
patients receiving dexamethasone. Low CRP values, in particular, might cause 
doctors not to notice early-onset infections. 
6.3 LONG-TERM HEALTH RELATED QUALITY OF LIFE WITH 
HNC PATIENTS AND MICROVASCULAR RECONSTRUCTION
There are surprisingly few studies published regarding long-term HRQoL after 
microvascular reconstruction surgery of HNC patients. Pierre et al. showed in their 
prospective study of 64 patients that long-term QoL after oncologic surgery and 
microvascular free flap reconstruction in patients with oral cancer is satisfactory 
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6. Discussion
(129). Bozec et al. studied long-term QoL and psychosocial outcomes after 
oropharyngeal cancer surgery and radial forearm free-flap reconstruction and 
observed that long-term QoL was well-preserved (170). In the current study, the 
mean 15D score at the 4.9-years follow-up point was significantly lower than at 
baseline.
Speech problems are expected to be common after surgery of oropharyngeal 
cancer. The dimensions of “speech” and “usual activities” were the most affected 
dimensions at the 4.9-years follow-up also in the current study. Psychological 
distress (swallowing and speech problems, changed appearance, fear of recurrence 
and death) is common, even long after treatment in HNC patients (171). In the 
present study, the dimension of “discomfort and symptoms”, and the psychological 
dimensions of “depression” and “distress” interestingly improved during the long-
term follow-up although the differences were not statistically significant. If any 
anxiety occurs during the treatment period or follow-up visits, patients will have 
access to psychotherapy in our hospital. This may improve the depression, as well 
as the continuity of treatment and regular controls are beneficial for mental health.
In this study population, the mean 15D score deteriorated in all patients 
in the same way, regardless of whether or not postoperative radiotherapy 
was received. The type of reconstruction and tumor score had no statistically 
significant effect on the follow-up 4.9-years mean 15D score.
6.4 MORTALITY 
6.4.1 SHORT-TERM MORTALITY AND INFLUENCE OF DEXAMETHASONE
There are different determinations for short-term mortality, including within 30-
180 days after operation or diagnosis (172, 173). In the current study, short-term 
mortality was defined as death within one year after primary surgery and long-term 
mortality as death later than one year after the operation. The hypothesis was that 
perioperatively administered dexamethasone may be harmful for the patients as it 
can increase postoperative complications and thus cause more serious side effects. 
It was anticipated that perioperative dexamethasone might have effects on patients’ 
short-term survival as it induces generalized immunosuppression and thus may 
cause more infectious complications. In addition, dexamethasone can significantly 
suppress cell proliferation and promote resistance to apoptosis in tumor cells (174, 
175). The novel finding of Study IV is in line with the hypothesis, as all patients 
who died within six months and most who died within one year of the operation, 
were in the DEX group. Almost all of them had postoperative complications. This 
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is understood to be the first prospective randomized study to investigate the effect 
of the use of GCs on mortality with operated reconstructive HNC patients.
6.4.2 LONG-TERM MORTALITY
Half of the deaths occurred within two years after the surgery. The 5-year survival of 
the current study was 65.6%, which can be considered good, and it was higher than 
reported in many other series of HNC patients with free flap reconstruction (147, 
176, 177). In the multivariate analysis, the most significant long-term predictors of 
death were distant metastases, CCI 5-9 and DEX group, whereas gender and age 
were not associated with long-term survival. Deceased patients were more likely 
to have had more advanced decease, need for gastrostoma, received more often 
postoperative chemotherapy, and more often locoregional or distal metastases 
in the follow-up. In these cases, postoperative chemotherapy is combined with 
radiotherapy and given in metastatic diseases, therefore the prognosis of these 
patients is worse originally. In the material of the current study, early death of 
patients also had a long-term effect, as the differences between the groups did not 
even out during the follow-up. The use of perioperative dexamethasone in HNC 
patients has been discontinued in the host institute because of the findings of the 
current studies.
6.4.3 CAUSES OF DEATH
There are few earlier studies that have reported causes of the death of HNC 
patients with microvascular reconstruction. The present study reported the primary 
disease (HNC) as the main cause of death in most (79%) of the patients, which 
is in line with findings by Ch’ng et al. and Lahtinen et al. (13, 178). Some studies 
have reported the second primary malignancy to be the leading cause of death 
among HNC patients, but these include all HNC patients, not only those with 
microvascular reconstruction (149, 179). In the current study, other malignancies 
were not predominating. 
6.5 LIMITATIONS OF THE THESIS AND FUTURE PROSPECTS
The relatively small size of the study population can be considered as a limitation 
of this thesis. However, patients in this study participated in a blinded prospective 
randomized dexamethasone study and formed a coherent and representative group 
of patients with a relatively rare type of cancer and microvascular reconstruction. 
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6. Discussion
Surgical procedure is very specific, and it took a long time to collect this material. 
Accordingly, the number of the patients may be considered quite sufficient, and 
this is a thoroughly conducted study in which the goal has been well defined. The 
impact of surgical margins on deaths was not analyzed in the cohort, however, 
which is a limitation. 
Perioperative dexamethasone is still used for this patient group in many centers. 
The findings of these articles are novel for HNC patients and the information of 
this thesis needs to be shared to the centers who are still using it. The effects of 
perioperative dexamethasone need to be studied in the future also with other 
types of cancer surgeries.
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7. CONCLUSIONS
At the beginning of this prospective study, it was hypothesized that reconstructive 
HNC patients receiving dexamethasone would recover faster. Contrary to 
early expectations, the results of this study showed that perioperative use of 
dexamethasone was harmful for this patient group and is not recommended for 
HNC patients requiring microvascular reconstruction. It is associated with major 
complications and short-term morbidity and it does not seem to significantly 
enhance immediate postoperative recovery or shorten ICU or hospital stay. 
There is more harm than benefit in the perioperative use of dexamethasone with 
reconstructive HNC patients. This study revealed the following key findings.
I
Perioperative use of dexamethasone did not benefit the HNC patients with 
microvascular reconstruction. Patients who received dexamethasone had 
significantly more major complications (need for second surgery within three 
weeks), especially surgical infections. Use of dexamethasone did not diminish the 
amount of neck swelling, length of ICU or hospital stay, or duration of intubation 
or tracheostomy.
II
Perioperative use of dexamethasone did not enhance recovery. Although 
dexamethasone decreased postoperative pain, it did not decrease nausea. There 
were no differences between the groups in postoperative mobilization, ability to 
drink fluids after surgery, or in other clinical measures of recovery. Patients required 
significantly more insulin and lactate levels were higher compared with controls. 
III
The long-term (4.9-years) HRQoL of operated HNC patients was significantly 
reduced than at baseline. The most affected dimensions were “speech” and “usual 
activities”. There was a significant difference at the 4.9-years follow-up in the 
mean 15D score between patients and the general population (patients 0.844 vs 
population 0.894, p=0.014).
IV
Perioperative use of dexamethasone increased short-term mortality in HNC 
patients with microvascular reconstruction within one year after surgery. In the 
multivariate analysis, the most important long-term (median 5.3 years) predictors 
of death were distant metastases, CCI 5-9 and DEX group. The most common 
cause of death after microvascular surgery for HNC was the primary disease (79% 
of all deceased). 
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QUALITY OF LIFE QUESTIONNAIRE (15D©)
Please read through all the alternative responses to each question before placing a cross (x)
against the alternative which best describes your present health status. Continue through all 15
questions in this manner, giving only one answer to each.
QUESTION 1.  MOBILITY
1 (  ) I am able to walk normally (without difficulty) indoors, outdoors and on stairs.
2 (  ) I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight
difficulties.
3 (  ) I am able to walk without help indoors (with or without an appliance), but outdoors
and/or on stairs only with considerable difficulty or with help from others.
4 (  ) I am able to walk indoors only with help from others.
5 (  ) I am completely bed-ridden and unable to move about.
QUESTION 2.  VISION
1 (  ) I see normally, i.e. I can read newspapers and TV text without difficulty (with or
without glasses).
2 (  ) I can read papers and/or TV text with slight difficulty (with or without glasses).
3 (  ) I can read papers and/or TV text with considerable difficulty (with or without glasses).
4 (  ) I cannot read papers or TV text either with glasses or without, but I can see enough to
walk about without guidance.
5 (  ) I cannot see enough to walk about without a guide, i.e. I am almost or completely blind.
QUESTION 3.  HEARING
1 (  ) I can hear normally, i.e. normal speech (with or without a hearing aid).
2 (  ) I hear normal speech with a little difficulty.
3 (  ) I hear normal speech with considerable difficulty; in conversation I need voices to be
louder than normal.
4 (  ) I hear even loud voices poorly; I am almost deaf.
5 (  ) I am completely deaf.
QUESTION 4.  BREATHING
1 ( ) I am able to breathe normally, i.e. with no shortness of breath or other breathing difficulty.
2 (  ) I have shortness of breath during heavy work or sports, or when walking briskly on flat
ground or slightly uphill.
3 (  ) I have shortness of breath when walking on flat ground at the same speed as others my age.
4 (  ) I get shortness of breath even after light activity, e.g. washing or dressing myself.
5 (  ) I have breathing difficulties almost all the time, even when resting.
15D©/Harri Sintonen (www.15D-instrument.net)
APPENDIX
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Appendix
QUESTION 5.   SLEEPING
1 (  ) I am able to sleep normally, i.e. I have no problems with sleeping.
2 (  ) I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes
waking at night.
3 (  ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept
enough.
4 (  ) I have great problems with sleeping, e.g. having to use sleeping pills often or routinely,
or usually waking at night and/or too early in the morning.
5 (  ) I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of
sleeping pills, or staying awake most of the night.
QUESTION 6.   EATING
1 (  ) I am able to eat normally, i.e. with no help from others.
2 (  ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with
special appliances).
3 (  ) I need some help from another person in eating.
4 (  ) I am unable to eat by myself at all, so I must be fed by another person.
5 (  ) I am unable to eat at all, so I am fed either by tube or intravenously.
QUESTION 7.  SPEECH
1 (  ) I am able to speak normally, i.e. clearly, audibly and fluently.
2 (  ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or
changes of pitch.
3 (  ) I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or
stammering.
4 (  ) Most people have great difficulty understanding my speech.
5 (  ) I can only make myself understood by gestures.
QUESTION 8. EXCRETION
1 (  ) My bladder and bowel work normally and without problems.
2 (  ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with
urination, or loose or hard bowels.
3 (  ) I have marked problems with my bladder and/or bowel function, e.g. occasional
'accidents', or severe constipation or diarrhea.
4 (  ) I have serious problems with my bladder and/or bowel function, e.g. routine 'accidents',
or need of catheterization or enemas.
5 (  ) I have no control over my bladder and/or bowel function.
QUESTION 9.   USUAL ACTIVITIES
1 (  ) I am able to perform my usual activities (e.g. employment, studying, housework, free-
time activities) without difficulty.
2 (  ) I am able to perform my usual activities slightly less effectively or with minor difficulty.
3 (  ) I am able to perform my usual activities much less effectively, with considerable
difficulty, or not completely.
4 (  ) I can only manage a small proportion of my previously usual activities.
5 (  ) I am unable to manage any of my previously usual activities.
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QUESTION 10.  MENTAL FUNCTION
1 (  ) I am able to think clearly and logically, and my memory functions well
2 (  ) I have slight difficulties in thinking clearly and logically, or my memory sometimes fails me.
3 (  ) I have marked difficulties in thinking clearly and logically, or my memory is somewhat
impaired.
4 (  ) I have great difficulties in thinking clearly and logically, or my memory is seriously
impaired.
5 (  ) I am permanently confused and disoriented in place and time.
QUESTION 11.   DISCOMFORT AND SYMPTOMS
1 (  )  I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
2 (  )  I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
3 (  )  I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
4 (  )  I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
5 (  )  I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
QUESTION 12.   DEPRESSION
1 (  )  I do not feel at all sad, melancholic or depressed.
2 (  )  I feel slightly sad, melancholic or depressed.
3 (  )  I feel moderately sad, melancholic or depressed.
4 (  )  I feel very sad, melancholic or depressed.
5 (  )  I feel extremely sad, melancholic or depressed.
QUESTION 13. DISTRESS
1 (  )  I do not feel at all anxious, stressed or nervous.
2 (  )  I feel slightly anxious, stressed or nervous.
3 (  )  I feel moderately anxious, stressed or nervous.
4 (  )  I feel very anxious, stressed or nervous.
5 (  )  I feel extremely anxious, stressed or nervous.
QUESTION 14.   VITALITY
1 (  )  I feel healthy and energetic.
2 (  )  I feel slightly weary, tired or feeble.
3 (  )  I feel moderately weary, tired or feeble.
4 (  )  I feel very weary, tired or feeble, almost exhausted.
5 (  )  I feel extremely weary, tired or feeble, totally exhausted.
QUESTION 15.  SEXUAL ACTIVITY
1 (  )  My state of health has no adverse effect on my sexual activity.
2 (  )  My state of health has a slight effect on my sexual activity.
3 (  )  My state of health has a considerable effect on my sexual activity.
4 (  )  My state of health makes sexual activity almost impossible.
5 (  )  My state of health makes sexual activity impossible.
QUESTION 5.   SLEEPING
1 (  ) I am able to sleep normally, i.e. I have no problems with sleeping.
2 (  ) I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes
waking at night.
3 (  ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept
enough.
4 (  ) I have great problems with sleeping, e.g. having to use sleeping pills often or routinely,
or usually waking at night and/or too early in the morning.
5 (  ) I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of
sleeping pills, or staying awake most of the night.
QUESTION 6.   EATING
1 (  ) I am able to eat normally, i.e. with no help from others.
2 (  ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with
special appliances).
3 (  ) I need some help from another person in eating.
4 (  ) I am unable to eat by myself at all, so I must be fed by another person.
5 (  ) I am unable to eat at all, so I am fed either by tube or intravenously.
QUESTION 7.  SPEECH
1 (  ) I am able to speak normally, i.e. clearly, audibly and fluently.
2 (  ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or
changes of pitch.
3 (  ) I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or
stammering.
4 (  ) Most people have great difficulty understanding my speech.
5 (  ) I can only make myself understood by gestures.
QUESTION 8. EXCRETION
1 (  ) My bladder and bowel work normally and without problems.
2 (  ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with
urination, or loose or hard bowels.
3 (  ) I have marked problems with my bladder and/or bowel function, e.g. occasional
'accidents', or severe constipation or diarrhea.
4 (  ) I have serious problems with my bladder and/or bowel function, e.g. routine 'accidents',
or need of catheterization or enemas.
5 (  ) I have no control over my bladder and/or bowel function.
QUESTION 9.   USUAL ACTIVITIES
1 (  ) I am able to perform my usual activities (e.g. employment, studying, housework, free-
time activities) without difficulty.
2 (  ) I am able to perform my usual activities slightly less effectively or with minor difficulty.
3 (  ) I am able to perform my usual activities much less effectively, with considerable
difficulty, or not completely.
4 (  ) I can only manage a small proportion of my previously usual activities.
5 (  ) I am unable to manage any of my previously usual activities.
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